. 2021 Jan 4;13:2. doi: 10.1186/s13195-020-00713-3

Table 1.

Participant characteristics of the Amsterdam Dementia Cohort (ADC) and ADNI cohorts

	ADC			ADNI
Characteristic	NC N = 740	MCI N = 591	AD dementia N = 1296	NC N = 371	MCI N = 622	AD dementia N = 228
MMSE, mean ± SD	28.2 ± 1.8	26.5 ± 2.4 ^a	20.5 ± 5 ^c	29.1 ± 1.2	27.7 ± 1.8 ^a	23.3 ± 2 ^c
Age, mean ± SD	59.6 ± 8.9	66.4 ± 8.2 ^a	66.2 ± 8.1 ^a	73.8 ± 5.9	72.4 ± 7.5 ^a	74.9 ± 8.1 ^b
Female, n (%)	306 (41.4%)	217 (36.7%) ^a	674 (52%) ^c	195 (52.6%)	255 (41%) ^a	95 (41.7%) ^c
APOE e4 carrier, n (%) NC	258 (36.3%)	287 (52.4%) ^a	791 (65.3%) ^c	103 (27.8%)	307 (49.4%) ^a	154 (67.5%) ^c
Innotest: T-tau (pg/ml), mean ± SD	296.4 ± 200.8	466.4 ± 303.6 ^a	716.6 ± 417.1 ^c	n.a.	n.a.	n.a.
Innotest: P-tau (pg/ml), mean ± SD	48.4 ± 22.7	66.8 ± 33.6 ^a	87.6 ± 39.5 ^c	n.a.	n.a.	n.a.
Innotest: Aβ42 (pg/ml), mean ± SD	1071.2 ± 246.9	859.1 ± 288.1 ^a	648.4 ± 166.6 ^c	n.a.	n.a.	n.a.
Innotest: Abnormal Aβ42 (< 813 pg/ml), n (%)	124 (16.8%)	326 (55.2%) ^a	1173 (90.5%) ^c	n.a.	n.a.	n.a.
Luminex T-tau (pg/ml), mean ± SD	n.a.	n.a.	n.a.	67.4 ± 32.8	90.4 ± 54.8 ^a	126.6 ± 61.4 ^c
Luminex P-tau (pg/ml), mean ± SD	n.a.	n.a.	n.a.	32.4 ± 18.8	39.2 ± 23.7 ^a	51.6 ± 30.7 ^c
Luminex Aβ42 (pg/ml), mean ± SD	n.a.	n.a.	n.a.	201.7 ± 51.9	171.2 ± 52.5 ^a	139.6 ± 38.8 ^c
Luminex Abnormal Aβ42 (< 192 pg/ml), n(%)	n.a.	n.a.	n.a.	156 (42%)	403 (64.8%) ^a	210 (92.1%) ^c
Elecsys T-tau (pg/ml), mean ± SD	n.a.	n.a.	n.a.	238.5 ± 90	284.9 ± 126.7 ^a	370.2 ± 144.4 ^c
Elecsys P-tau (pg/ml), mean ± SD	n.a.	n.a.	n.a.	21.9 ± 9.2	27.6 ± 14.4 ^a	36.9 ± 15.7 ^c
Elecsys Aβ42 (pg/ml), mean ± SD	n.a.	n.a.	n.a.	1337 ± 647.9	1020.7 ± 554.8 ^a	694.6 ± 420.7 ^c
Elecsys Abnormal Aβ42 (< 880 pg/ml), n (%)	n.a.	n.a.	n.a.	104 (28%)	325 (53%) ^a	189 (85%) ^c

n.a. not available, NC cognitively normal, MCI mild cognitive impairment, AD Alzheimer’s disease

^aDiffers from NC with p < .05

^bDiffers from MCI with p < .001

^cDiffers from MCI and NC with p < .001